Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study
RFK Jr. to Reinstate 20% of HHS Staff Laid off After DOGE Errors
U.S. Stocks Poised for Earnings Surprises in April
Sarepta, Roche Seek to Resume Elevidys Trials
European Stocks Poised for Earnings Surprises in April
Johnson & Johnson Announces TREMFYA Is The First And Only IL-23 Inhibitor To Reduce Both The Signs And Symptoms And The Progression Of Structural Damage In Adults Living With Active Psoriatic Arthritis